VRNA Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: August 09, 2025
Report Source: 2025 2nd Quarter Report
Verona Pharma PLC. Stock Analysis VRNA
United States Health Care Mid Cap Report: Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. The company is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The firm's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The firm's wholly owned subsidiary is Verona Pharma, Inc.
Read More Verona Pharma PLC (VRNA) Chart
Verona Pharma PLC (VRNA) vs FTSE 100 Comparative Returns
Analysis of Verona Pharma PLC (VRNA) stock performance compared to the broader market (FTSE 100) across multiple timeframes.
YTD Performance
- Verona Pharma P... (VRN...) 130.21%
- FTSE 100 13.98%
Verona Pharma PLC Outperformed FTSE 100 by 116.23%
1Y Performance
- Verona Pharma P... (VRN...) 233.99%
- FTSE 100 12.2%
Verona Pharma PLC Outperformed FTSE 100 by 221.79%
3Y Performance
- Verona Pharma P... (VRN...) 955.38%
- FTSE 100 36.53%
Verona Pharma PLC Outperformed FTSE 100 by 918.85%
5Y Performance
- Verona Pharma P... (VRN...) 1641.21%
- FTSE 100 58.67%
Verona Pharma PLC Outperformed FTSE 100 by 1582.54%
Key Statistics of Verona Pharma PLC (VRNA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$106.85Volume
1.87MP/E Ratio (TTM)
-52 Week Range
Market Cap
6.29BAvg. Volume
1.62MDividend Yield
-Financial Metrics & Statements of Verona Pharma PLC (VRNA)
Community-Curated Collections with Verona Pharma PLC (VRNA)
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
shariah list nifty 50
By trading view
2195 Followers
HALAL STOCK of india
By Aasif Khan
1957 Followers
My Halal AI Stocks Technology - 2024
By Doniyor Akhmadjon
670 Followers
Recent Halal Top Performers US
By Doniyor Akhmadjon
455 Followers
Dow Jones Industrial Average Index
By Dilnoza Mirsaidova
240 Followers
Zero Debt Stocks in India
By Javokhir Suyundikov
127 Followers
1st HALAL NIFTY SMALLCAP 250
By Abdul Mannan
121 Followers
Halal stocks in INDIA
By Altaf Khan
115 Followers
Halal Divident Stock
By Monirul Islam
109 Followers
IT Sector Stocks in India
By Javokhir Suyundikov
109 Followers
FAQ's for Verona Pharma PLC (VRNA)
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Related Halal Stocks to Verona Pharma PLC (VRNA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
